Jade Biosciences, Inc. (JBIO)
| Market Cap | 305.71M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -93.96M |
| Shares Out | 32.63M |
| EPS (ttm) | -18.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 156,190 |
| Open | 9.73 |
| Previous Close | 9.79 |
| Day's Range | 8.98 - 9.84 |
| 52-Week Range | 2.07 - 13.50 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 20.00 (+113.45%) |
| Earnings Date | Nov 5, 2025 |
About JBIO
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. It also develops JADE201 and JADE-003, which are in preclinical development stage. The company has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. was founded in 2024 and is headquartered in Waltham, Mas... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for JBIO stock is "Strong Buy." The 12-month stock price target is $20.0, which is an increase of 113.45% from the latest price.
News
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025
Presentations to highlight JADE101's preclinical safety profile and translational framework guiding its clinical development in IgA nephropathy JADE101 is an investigational, potentially best-in-class...
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases
JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell d...
Jade Biosciences Announces $135 Million Private Placement
SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on dev...
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy
Selective APRIL inhibition has shown disease-modifying potential in IgAN patient clinical trials JADE101 has shown ultra-high binding affinity and a differentiated pharmacokinetic and pharmacodynamic ...
Jade Biosciences to Participate in Upcoming Conferences
SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies ...
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Presented preclinical data for JADE101 at the 62nd European Renal Association Congress, highlighting its potential as a best-in-class anti-APRIL monoclonal antibody for IgA nephropathy Phase 1 healthy...
Jade Biosciences to Participate in Two Upcoming Investor Conferences
SAN FRANCISCO and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies ...
Jade Biosciences Appoints Brad Dahms as Chief Financial Officer
SAN FRANCISCO and VANCOUVER, British Columbia, July 01, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies f...
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy
Preclinical data highlighted JADE101's femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppression In non-human primates, JADE101 sh...
Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress
SAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies f...
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
Completed reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027 Lead candidate JADE101 expected to ent...
Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference
SAN FRANCISCO and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies f...